Liquid Cystatin C Assay– a Good Indicator of GFR
By LabMedica International staff writers Posted on 27 Dec 2011 |
A liquid ready-to-use cystatin C assay provides a good indicator of glomerular filtration rate (GRF). As a more sensitive maker of renal dysfunction, cystatin C offers several advantages over traditional creatinine assays.
Cystatin C is unaffected by nonrenal factors including muscle mass, weight, height, age, gender, diet and drugs. Therefore it is particularly useful in cases where creatinine measurement is not appropriate e.g., in individuals who are obese, malnourished, or who have liver disease.
The Randox (Crumlin, United Kingdom) cystatin C assay is based on an immunoturbidimetric method and is suitable for use on a wide range of chemistry analyzers. All reagents are supplied liquid ready to use for added convenience; furthermore, reagents are stable for 28 days at +10 °C onboard the analyzer, minimizing the possibility of reagent waste.
The assay has a wide measuring range of 0.4 to 10 mg/L allowing both normal and abnormal values to be measured accurately and reliably without the need for additional dilutions. Further benefits include precision (CVs under 5%) and limited interference from bilirubin, hemoglobin, triglycerides, and intralipids. A full range of supporting quality controls and calibrators are also available.
Cystatin C is sensitive to changes in the “creatinine blind” range enabling detection of early reductions in GFR and subsequent early treatment of kidney disease. Cystatin C has several other advantages over creatinine; the ability of cystatin C to detect even small changes in GFR makes it the ideal marker for dosing medication eliminated by the kidneys. Cystatin C is also the preferred marker for estimating GFR in infants, the elderly, diabetics, and those with reduced muscle mass.
Traditionally creatinine was the most widely used marker of GFR and kidney function but several recent studies have documented cystatin C as a far superior and sensitive marker. Cystatin C is produced at a constant rate throughout the body and is removed and broken down by the kidneys, levels will therefore remain steady if the kidneys are working efficiently and the GFR is normal.
The prevalence of chronic kidney disease continues to increase dramatically as does the burden on healthcare resources. The early detection of kidney disease is crucial in order to lower healthcare costs, avoid disease progression, and reduce the need for dialysis or transplantation.
Related Links:
Randox
Cystatin C is unaffected by nonrenal factors including muscle mass, weight, height, age, gender, diet and drugs. Therefore it is particularly useful in cases where creatinine measurement is not appropriate e.g., in individuals who are obese, malnourished, or who have liver disease.
The Randox (Crumlin, United Kingdom) cystatin C assay is based on an immunoturbidimetric method and is suitable for use on a wide range of chemistry analyzers. All reagents are supplied liquid ready to use for added convenience; furthermore, reagents are stable for 28 days at +10 °C onboard the analyzer, minimizing the possibility of reagent waste.
The assay has a wide measuring range of 0.4 to 10 mg/L allowing both normal and abnormal values to be measured accurately and reliably without the need for additional dilutions. Further benefits include precision (CVs under 5%) and limited interference from bilirubin, hemoglobin, triglycerides, and intralipids. A full range of supporting quality controls and calibrators are also available.
Cystatin C is sensitive to changes in the “creatinine blind” range enabling detection of early reductions in GFR and subsequent early treatment of kidney disease. Cystatin C has several other advantages over creatinine; the ability of cystatin C to detect even small changes in GFR makes it the ideal marker for dosing medication eliminated by the kidneys. Cystatin C is also the preferred marker for estimating GFR in infants, the elderly, diabetics, and those with reduced muscle mass.
Traditionally creatinine was the most widely used marker of GFR and kidney function but several recent studies have documented cystatin C as a far superior and sensitive marker. Cystatin C is produced at a constant rate throughout the body and is removed and broken down by the kidneys, levels will therefore remain steady if the kidneys are working efficiently and the GFR is normal.
The prevalence of chronic kidney disease continues to increase dramatically as does the burden on healthcare resources. The early detection of kidney disease is crucial in order to lower healthcare costs, avoid disease progression, and reduce the need for dialysis or transplantation.
Related Links:
Randox
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines